A proof-of Concept Study to Assess Safety and Tolerability of HM15421/GC1134A in Patients With Fabry Disease

An Open Label, Dose Range, Proof-of-Concept Study to Assess the Safety and Efficacy of HM15421/GC1134A in Patients With Fabry Disease

This Phase 1/2 first-in-human (FIH) study is designed to evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of HM15421 in patients with FD.

Study Overview

• Status: Recruiting
• Conditions: Fabry Disesase
• Intervention / Treatment: Drug: HM15421/GC1134A

• Study Type: Interventional
• Enrollment (Estimated): 18
• Phase: Phase 2; Phase 1

Contacts and Locations

• Study Contact: Name: GC Biopharma; Phone Number: +82-031-260-9300; Email: GC1134A@gccorp.com

Study Locations

• Argentina
  • Buenos Aires, Argentina, C1199ABB
    • Recruiting
    • Hospital Italiano de Buenos Aires
    • Principal Investigator: Marcelo Rugiero, MD
  • Santa Fe Province
    • Rosario, Santa Fe Province, Argentina, S2000
      • Recruiting
      • Centro Medico IPAM
      • Principal Investigator: Sebastian Jaurretche, MD
• South Korea
  • Seoul, South Korea, 03722
    • Recruiting
    • Yonsei University, College of Medicine
    • Principal Investigator: Geu-Ru Hong, MD
  • Gyeongsangnam-do
    • Yangsan, Gyeongsangnam-do, South Korea, 50612
      • Recruiting
      • Pusan National University Children's Hospital in Yangsan
      • Principal Investigator: Chong Kun Cheon, MD
• United States
  • California
    • Los Angeles, California, United States, 90095
      • Recruiting
      • David Geffen School of Medicine UCLA, UCLA Health
      • Principal Investigator: Anjay Rastogi, MD
  • Kansas
    • Kansas City, Kansas, United States, 66160-8500
      • Recruiting
      • University of Kansas School of Medicine
      • Principal Investigator: Ahmad M. Tuffaha, MD
  • Minnesota
    • Minneapolis, Minnesota, United States, 55455
      • Recruiting
      • University of Minnesota
      • Principal Investigator: Chester B. Whitley, MD
  • Ohio
    • Cincinnati, Ohio, United States, 45229-3039
      • Recruiting
      • Children's Hospital Medical Center
      • Principal Investigator: Robert J. Hopkin, MD
  • Pennsylvania
    • Pittsburgh, Pennsylvania, United States, 15224
      • Recruiting
      • University of Pittsburgh Medical Center Children's Hoispital of Pittsburgh
      • Principal Investigator: Damara Ortiz, MD
  • Virginia
    • Fairfax, Virginia, United States, 22030
      • Recruiting
      • Lysosomal and Rare Disorders Research and Treatment Center
      • Principal Investigator: Ozlem Goker-Alpan, MD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Participants must be ≥ 18 years of age or age considered as adult in the respective country at the time of signing the informed consent.
2. Documented diagnosis of FD with clinical symptoms.
3. Females: historical genetic test results based on identification of pathogenic or likely pathogenic GLA variant of FD.
4. Males: Plasma and/or leucocyte alpha galactosidase activity (by activity assay) less than lower limit of normal (LLN in plasma=3.2 nmol/hr/mL, LLN in leucocytes=32 nmol/hr/mg/protein).
5. Patients who are naive or have not received FD therapy including investigational therapy for FD within the past 6 months prior to screening and have negative ADA testing at screening.
6. Estimated glomerular filtration rate (eGFR) ≥ 60 mL/min/1.73 m2 by Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation.
7. Plasma lyso-Gb3 levels greater than 1.5 times the upper limit of normal (ULN).

8. Male participants:

   • Male participants are eligible to participate if they agree to the following during the study treatment period:
   • Refrain from donating sperm,

   PLUS either:

   • Be abstinent from heterosexual intercourse with a woman of childbearing potential (WOCBP) as their preferred and usual lifestyle (abstinent on a longterm and persistent basis) and agree to remain abstinent, OR
   • Must agree to use a male condom when engaging in any activity that allows for passage of ejaculate to another person,
   • In addition to male condom, use of highly effective method of contraception may be considered in WOCBP partners of male participants.

9. Female participants:

   • Female participants are eligible to participate if they are not pregnant or breastfeeding, and at least 1 of the following conditions applies:

     • Is not a WOCBP, OR
     • Is a WOCBP and using a contraceptive method that is highly effective (with a failure rate of < 1% per year), preferably with low user dependency, starting at least one menstrual cycle before first study drug administration and continuing for at least 30 days after the end of systemic exposure of the study drug and agrees not to donate eggs (ova, oocytes) for the purpose of reproduction during this period. The Investigator should evaluate the effectiveness of the contraceptive method in relationship to the first dose of study drug.
     • A WOCBP must have a negative highly sensitive pregnancy test (urine or serum as required by local regulations) within 24 hours before the first dose of study drug.
     • If a urine test cannot be confirmed as negative (eg, an ambiguous result), a serum pregnancy test is required. In such cases, the participant must be excluded from participation if the serum pregnancy result is positive.
   • Women whose postmenopausal status is recent, may perform additional follicle stimulating hormone (FSH) testing.

   Informed Consent

10. Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.

Exclusion Criteria:

1. Women who are pregnant, planning to become pregnant during the study, or are breast feeding.
2. History of dialysis or renal transplantation.
3. CKD stage ≥ 3.
4. History of acute kidney injury within 12 months prior to screening, including specific kidney diseases (eg, acute interstitial nephritis, acute glomerular and vasculitic renal diseases); non-specific conditions (eg, ischemia, toxic injury); as well as extrarenal pathology (eg, prerenal azotemia, and acute postrenal obstructive nephropathy).
5. Urine protein to creatinine ratio (UPCR) > 0.5 g/g and not treated with an angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB).
6. Known history of hypersensitivity to any ingredient in the investigational product and to Gadolinium contrast agent that is not managed by the use of premedication.
7. Cardiovascular event (myocardial infarction, unstable angina) within 6 months before screening.
8. Congestive heart failure New York Heart Association (NYHA) Class IV
9. History of stroke.
10. Pacemaker or other contraindication for magnetic resonance imaging (MRI) scanning.
11. Angiotensin converting enzyme inhibitor or ARB therapy initiated or dose changed in the 4 weeks prior to screening.
12. Patients who received investigational gene therapy for FD.
13. Participation in other studies involving study drugs within 4 weeks prior to study entry and/or during study participation.
14. Participating in interventional study or using compassionate access product for FD. Participants who have participated in interventional trials for conditions not related to FD should be enrolled after the adequate wash out period is over, which is 5 half-lives or 30 days whichever is longer.
15. Presence of human immunodeficiency virus (HIV) and/or active (acute or chronic) hepatitis B and/or Hepatitis C infections.
16. Presence of any medical, emotional, behavioral, or psychological condition that, in the judgment of the Investigator and/or Medical Monitor, would interfere with the participant's compliance with the requirements of the study.
17. Participants who may have history of deliberate self-harm or suicidal ideation.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Sequential Assignment
• Masking: None (Open Label)

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Cohort 1; Low dose	Drug: HM15421/GC1134A; SC
Experimental: Cohort 2; Mid dose	Drug: HM15421/GC1134A; SC
Experimental: Cohort 3; High dose	Drug: HM15421/GC1134A; SC

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Incidences and characteristics of adverse events	Up to 48 weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Maximum serum concentration (Cmax)	PK parameter	Up to 48 weeks
Time to reach maximum serum concentration (Tmax)	PK parameter	Up to 48 weeks
Trough serum concentration (Ctrough)	PK parameter	Up to 48 weeks
Area under the concentration-time curve in one dosing interval (AUC0-tau)	PK parameter	Up to 48 weeks
Terminal elimination half-life (t1/2)	PK parameter	Up to 48 weeks
Apparent clearance at steady state (CLss/F)	PK parameter	Up to 48 weeks
Apparant volume of distribution at steady state during the terminal phase (Vss/F)	PK parameter	Up to 48 weeks
Plasma Lyso-Gb3 level	PD parameter	Up to 48 weeks
Plasma Gb3 level	PD parameter	Up to 48 weeks
Urine Lyso-Gb3 level	PD Parameter	Up to 48 weeks
Urine Creatinine level	PD parameter	Up to 48 weeks
Urine Albumin level	PD parameter	Up to 48 weeks
Total Urine Protein Level	PD parameter	Up to 48 weeks
Urine Protein to Creatinine Ratio	PD parameter	Up to 48 weeks
Urine Albumin to Creatinine Ratio	PD parameter	Up to 48 weeks
Change in eGFR	PD parameter	Up to 48 weeks
Change in kidney Gb3 accumulation using the quantative Barisoni Lipid Inclusion Scoring System	PD parameter	Up to 48 weeks

Collaborators and Investigators

• Sponsor: GC Biopharma Corp
• Collaborators: Hanmi Pharmaceutical Company Limited

Study record dates

Study Major Dates

• Study Start (Actual): May 14, 2025
• Primary Completion (Estimated): August 30, 2028
• Study Completion (Estimated): August 30, 2028

Study Registration Dates

• First Submitted: February 19, 2025
• First Submitted That Met QC Criteria: February 27, 2025
• First Posted (Actual): March 5, 2025

Study Record Updates

• Last Update Posted (Estimated): November 4, 2025
• Last Update Submitted That Met QC Criteria: November 2, 2025
• Last Verified: November 1, 2025

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Cerebrovascular Disorders; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Vascular Diseases; Cardiovascular Diseases; Metabolism, Inborn Errors; Genetic Diseases, Inborn; Metabolic Diseases; Lipid Metabolism Disorders; Genetic Diseases, X-Linked; Lysosomal Storage Diseases; Brain Diseases, Metabolic, Inborn; Brain Diseases, Metabolic; Lipid Metabolism, Inborn Errors; Lysosomal Storage Diseases, Nervous System; Cerebral Small Vessel Diseases; Sphingolipidoses; Lipidoses; Fabry Disease
• Other Study ID Numbers: GC1134A_FD_P1201

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No